We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Molecular Virus-Testing Platform Released in Europe

By HospiMedica staff writers
Posted on 03 Oct 2006
An automated branched DNA (bDNA) molecular system for viral-load testing of human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) in serum and blood plasma is now available in Europe.

The system provides an easy-to-use molecular testing platform suitable for the general hospital and molecular laboratory. More...
Its touch screen interface and complete "load and go” bDNA automation includes on-board temperature control of assay reagents, on-board preparation of several assay reagents, and automated delivery of all assay reagents to micro wells. These features significantly reduce hands-on time and improve workflow and testing flexibility for mid- to high-volume laboratories.

This new system, called Versant 440, was developed by Bayer Healthcare, Diagnostics Division (Tarrytown, NY, USA), which is a subsidiary of Bayer AG (Leverkusen, Germany). It can process 12-168 patient samples per run and is compatible with a laboratory information system (LIS) through the Bayer bi-directional interface. The system has received the CE Mark.

"This addition allows us to offer a more robust portfolio with complete bDNA automation to the molecular diagnostics marketplace in Europe,” said Tony Bihl, president, Bayer Diagnostics. "The Versant 440 system reinforces Bayer Diagnostics' focus on satisfying the needs of hospitals and molecular laboratories.”



Related Links:
Bayer Healthcare

Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Wound Irrigation Solution
Prontosan®
Medical Examination & Procedure Light
Vega 80
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.